Skip to main content
Top
Published in: Japanese Journal of Ophthalmology 2/2022

01-03-2022 | Macular Degeneration | Clinical Investigation

Assessment of choriocapillaris/Sattler and Haller layer changes after intravitreal injection in eyes with neovascular age-related macular degeneration: aflibercept vs ranibizumab

Authors: Orhan Altunel, Cemal Ozsaygili

Published in: Japanese Journal of Ophthalmology | Issue 2/2022

Login to get access

Abstract

Purpose

To evaluate the changes in choriocapillaris (CC)/Sattler and Haller layer thicknesses in eyes with neovascular age-related macular degeneration (nAMD) after aflibercept or ranibizumab injections.

Study design

Retrospective.

Methods

A total of 70 eyes of 70 patients with treatment-naïve exudative nAMD were treated with 3 consecutive injections of aflibercept (IVA) or ranibizumab (IVR). CC/Sattler and Haller layer thicknesses were measured at the nasal and temporal regions 1000 µm from the center of the fovea by enhanced-depth imaging optical coherence tomography at baseline and after the 3 monthly intravitreal injections. In addition, the hyperfluorescence region (HF) was measured as the largest horizontal diameter of the hyperfluorescence area on the early-middle phase fluorescein angiographic images at baseline and after the 3 loading doses.

Results

After the 3 consecutive injections, the mean reductions in the nasal/temporal CC/Sattler layer thicknesses in the IVR and IVA groups were  – 10.1 ± 2.3/ – 8.5 ± 1.8 and  – 25.2 ± 15.2/ – 19.4 ± 12.8 μm, respectively. Also, the mean reductions in the nasal/temporal Haller layer thicknesses in the IVR and IVA groups were  – 6.5 ± 3.6/ – 7.2 ± 7.9 and  – 9.5 ± 8.0/ – 7.0 ± 6.2 μm, respectively. The changes in the CC/Sattler layer thicknesses of the IVA group were greater than those of the IVR group (P < .001); however, the changes in the Haller layer thickness were similar between the groups (P > .05). The mean decrease in the HF size of the IVA group was greater than that of the IVR group (P < .001).

Conclusions

Aflibercept treatment has a more pronounced effect on the CC/Sattler layer. Such results may indicate that aflibercept treatment influences choroidal neovascularization, possibly by reducing the capillary permeability associated with active neovascularization in the CC layer.
Literature
1.
go back to reference Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA Ophthalmol. 2004;291:1900–1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA Ophthalmol. 2004;291:1900–1.
2.
go back to reference Korb CA, Kottler UB, Wolfram C, Hoehn R, Schulz A, Zwiener I, et al. Prevalence of age-related macular degeneration in a large European cohort: results from the population-based Gutenberg Health Study. Graefes Arch Clin Exp Ophthalmol. 2014;252:1403–11.CrossRef Korb CA, Kottler UB, Wolfram C, Hoehn R, Schulz A, Zwiener I, et al. Prevalence of age-related macular degeneration in a large European cohort: results from the population-based Gutenberg Health Study. Graefes Arch Clin Exp Ophthalmol. 2014;252:1403–11.CrossRef
3.
go back to reference Klein R, Klein BEK, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2007;114:253–62.CrossRef Klein R, Klein BEK, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2007;114:253–62.CrossRef
4.
go back to reference Nickla DL, Wallman J. The multifunctional choroid. Prog Retin Eye Res. 2010;29:144–68.CrossRef Nickla DL, Wallman J. The multifunctional choroid. Prog Retin Eye Res. 2010;29:144–68.CrossRef
5.
go back to reference McLeod DS, Grebe R, Bhutto I, Merges C, Baba T, Lutty GA. Relationship between RPE and choriocapillaris in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009;50:4982–91.CrossRef McLeod DS, Grebe R, Bhutto I, Merges C, Baba T, Lutty GA. Relationship between RPE and choriocapillaris in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009;50:4982–91.CrossRef
6.
go back to reference Lipecz A, Miller L, Kovacs I, Czakó C, Csipo T, Baffi J, et al. Microvascular contributions to age-related macular degeneration (AMD): from mechanisms of choriocapillaris aging to novel interventions. Geroscience. 2019;41:813–45.CrossRef Lipecz A, Miller L, Kovacs I, Czakó C, Csipo T, Baffi J, et al. Microvascular contributions to age-related macular degeneration (AMD): from mechanisms of choriocapillaris aging to novel interventions. Geroscience. 2019;41:813–45.CrossRef
7.
go back to reference Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98:1144–67.CrossRef Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98:1144–67.CrossRef
8.
go back to reference Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Kawasaki R, et al. Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159:627–33.CrossRef Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Kawasaki R, et al. Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159:627–33.CrossRef
9.
go back to reference Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. Ophthalmology. 2012;119:1621–7.CrossRef Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. Ophthalmology. 2012;119:1621–7.CrossRef
10.
go back to reference Branchini L, Regatieri C, Adhi M, Flores-Moreno I, Manjunath V, Fujimoto JG, et al. Effect of intravitreous anti-vascular endothelial growth factor therapy on choroidal thickness in neovascular age related macular degeneration using spectral domain optical coherence tomography. JAMA Ophthalmol. 2013;13:693–4.CrossRef Branchini L, Regatieri C, Adhi M, Flores-Moreno I, Manjunath V, Fujimoto JG, et al. Effect of intravitreous anti-vascular endothelial growth factor therapy on choroidal thickness in neovascular age related macular degeneration using spectral domain optical coherence tomography. JAMA Ophthalmol. 2013;13:693–4.CrossRef
11.
go back to reference Spaide RF, Koizumi H, Pozzoni MC. Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol. 2008;146:496–500.CrossRef Spaide RF, Koizumi H, Pozzoni MC. Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol. 2008;146:496–500.CrossRef
12.
go back to reference Freund KB, Zweifel SA, Engelbert M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina. 2010;30:1333–49.CrossRef Freund KB, Zweifel SA, Engelbert M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina. 2010;30:1333–49.CrossRef
13.
go back to reference Age-Related Eye Disease Research Study Group. The Age- Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study Report Number 6. Am J Ophthalmol. 2001;132:668–81.CrossRef Age-Related Eye Disease Research Study Group. The Age- Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study Report Number 6. Am J Ophthalmol. 2001;132:668–81.CrossRef
14.
go back to reference Manjunath V, Goren J, Fujimoto JG, Duker JS. Analysis of choroidal thickness in age-related macular degeneration using spectral-domain optical coherence tomography. Am J Ophthalmol. 2011;152:553–8.CrossRef Manjunath V, Goren J, Fujimoto JG, Duker JS. Analysis of choroidal thickness in age-related macular degeneration using spectral-domain optical coherence tomography. Am J Ophthalmol. 2011;152:553–8.CrossRef
15.
go back to reference Branchini LA, Adhi M, Regatieri CV, Nandakumar N, Liu JJ, Laver N, et al. Analysis of choroidal morphologic features and vasculature in healthy eyes using spectral-domain optical coherence tomography. Ophthalmology. 2013;120:1901–8.CrossRef Branchini LA, Adhi M, Regatieri CV, Nandakumar N, Liu JJ, Laver N, et al. Analysis of choroidal morphologic features and vasculature in healthy eyes using spectral-domain optical coherence tomography. Ophthalmology. 2013;120:1901–8.CrossRef
16.
go back to reference Yun C, Oh J, Ahn J, Hwang SY, Lee B, Kim SW, et al. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2016;254:1693–702.CrossRef Yun C, Oh J, Ahn J, Hwang SY, Lee B, Kim SW, et al. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2016;254:1693–702.CrossRef
17.
go back to reference Razavi S, Souied EH, Darvizeh F, Querques G. Assessment of choroidal topographic changes by swept-source optical coherence tomography after intravitreal ranibizumab for exudative age-related macular degeneration. Am J Ophthalmol. 2015;160:1006–13.CrossRef Razavi S, Souied EH, Darvizeh F, Querques G. Assessment of choroidal topographic changes by swept-source optical coherence tomography after intravitreal ranibizumab for exudative age-related macular degeneration. Am J Ophthalmol. 2015;160:1006–13.CrossRef
18.
go back to reference Kaya F. Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: ranibizumab versus aflibercept. J Fr Ophthalmol. 2017;40:832–8.CrossRef Kaya F. Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: ranibizumab versus aflibercept. J Fr Ophthalmol. 2017;40:832–8.CrossRef
19.
go back to reference Inan S, Baysal Z, Inan UU. Long-term changes in submacular choroidal thickness after intravitreal ranibizumab therapy for neovascular age-related macular degeneration: 14-mo follow-up. Curr Eye Res. 2019;44:908–15.CrossRef Inan S, Baysal Z, Inan UU. Long-term changes in submacular choroidal thickness after intravitreal ranibizumab therapy for neovascular age-related macular degeneration: 14-mo follow-up. Curr Eye Res. 2019;44:908–15.CrossRef
20.
go back to reference Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171–85.CrossRef Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171–85.CrossRef
21.
go back to reference dell’Omo R, Cassetta M, dell’Omo E, Salvatore AD, Hughes JM, Aceto F, et al. Aqueous humour levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization: a prospective, case-control study. Am J Ophthalmol. 2012;153:155–61.CrossRef dell’Omo R, Cassetta M, dell’Omo E, Salvatore AD, Hughes JM, Aceto F, et al. Aqueous humour levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization: a prospective, case-control study. Am J Ophthalmol. 2012;153:155–61.CrossRef
22.
go back to reference Kim JH, Chang YS, Lee TG, Kim CG. Choroidal vascular hyperpermeability and punctate hyperfluorescent spot in choroidal neovascularization. Invest Ophthalmol Vis Sci. 2015;56:1909–15.CrossRef Kim JH, Chang YS, Lee TG, Kim CG. Choroidal vascular hyperpermeability and punctate hyperfluorescent spot in choroidal neovascularization. Invest Ophthalmol Vis Sci. 2015;56:1909–15.CrossRef
23.
go back to reference Hata M, Oishi A, Tsujikawa A, Yamashiro K, Miyake M, Ooto S, et al. Efficacy of intravitreal injection of aflibercept in neovascular age-related macular degeneration with or without choroidal vascular hyperpermeability. Invest Ophthalmol Vis Sci. 2014;55:7874–80.CrossRef Hata M, Oishi A, Tsujikawa A, Yamashiro K, Miyake M, Ooto S, et al. Efficacy of intravitreal injection of aflibercept in neovascular age-related macular degeneration with or without choroidal vascular hyperpermeability. Invest Ophthalmol Vis Sci. 2014;55:7874–80.CrossRef
24.
go back to reference Jirarattanasopa P, Ooto S, Nakata I, Tsujikawa A, Yamashiro K, Oishi A, et al. Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2012;53:3663–72.CrossRef Jirarattanasopa P, Ooto S, Nakata I, Tsujikawa A, Yamashiro K, Oishi A, et al. Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2012;53:3663–72.CrossRef
25.
go back to reference Sacu S, Pemp B, Weigert G, Matt G, Garhofer G, Pruente C, et al. Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion. Invest Ophthalmol Vis Sci. 2011;52:3046–50.CrossRef Sacu S, Pemp B, Weigert G, Matt G, Garhofer G, Pruente C, et al. Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion. Invest Ophthalmol Vis Sci. 2011;52:3046–50.CrossRef
26.
go back to reference Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1–29.CrossRef Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1–29.CrossRef
27.
go back to reference Julien S, Biesemeier A, Taubitz T, Schraermeyer U. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. Br J Ophthalmol. 2014;98:813–25.CrossRef Julien S, Biesemeier A, Taubitz T, Schraermeyer U. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. Br J Ophthalmol. 2014;98:813–25.CrossRef
28.
go back to reference Lee H, Lee M, Kim MA, Chung H, Kim HC. Association of treatment response with quantitative changes in choroidal neovascularization and choroidal vessel in neovascular age-related macular degeneration. Retina. 2020;40:1704–18.CrossRef Lee H, Lee M, Kim MA, Chung H, Kim HC. Association of treatment response with quantitative changes in choroidal neovascularization and choroidal vessel in neovascular age-related macular degeneration. Retina. 2020;40:1704–18.CrossRef
29.
go back to reference Metelitsina TI, Grunwald JE, DuPont JC, Ying GS, Brucker AJ, Dunaief JL. Foveolar choroidal circulation and choroidal neovascularization in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49:358–63.CrossRef Metelitsina TI, Grunwald JE, DuPont JC, Ying GS, Brucker AJ, Dunaief JL. Foveolar choroidal circulation and choroidal neovascularization in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49:358–63.CrossRef
30.
go back to reference Kang HM, Kwon HJ, Yi JH, Lee CS, Lee SC. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration. Am J Ophthalmol. 2014;157:1013–21.CrossRef Kang HM, Kwon HJ, Yi JH, Lee CS, Lee SC. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration. Am J Ophthalmol. 2014;157:1013–21.CrossRef
31.
go back to reference Gharbiya M, Iannetti L, Parisi F, Vico UD, Mungo ML, Marenco M. Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Biomed Res Int. 2014;54:2737. Gharbiya M, Iannetti L, Parisi F, Vico UD, Mungo ML, Marenco M. Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Biomed Res Int. 2014;54:2737.
Metadata
Title
Assessment of choriocapillaris/Sattler and Haller layer changes after intravitreal injection in eyes with neovascular age-related macular degeneration: aflibercept vs ranibizumab
Authors
Orhan Altunel
Cemal Ozsaygili
Publication date
01-03-2022
Publisher
Springer Japan
Published in
Japanese Journal of Ophthalmology / Issue 2/2022
Print ISSN: 0021-5155
Electronic ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-021-00894-w

Other articles of this Issue 2/2022

Japanese Journal of Ophthalmology 2/2022 Go to the issue